A phase I multiple-dose, dose-escalation study to evaluate the safety of MEDI-507, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to patients with plaque psoriasis

A phase I multiple-dose, dose-escalation study to evaluate the safety of MEDI-507, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to patients with plaque psoriasis (PI: McCall, Co-I: Chen) 1% effort 3 subjects

Awarded By

  • MedImmune MI-CP062

Contributors

Amount

  • $55,480.00

Start/End

  • September 1, 2000 - April 30, 2002